{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:13:02Z","timestamp":1790867582158,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["NO769\/1-1"],"award-info":[{"award-number":["NO769\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Luebeck"},{"name":"University Medical Center Giessen and Marburg (UKGM)"},{"name":"Tongji University, Shanghai, PRC"},{"name":"German National Genome Research Network","award":["01GS08136-4"],"award-info":[{"award-number":["01GS08136-4"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HO2402\/6-1"],"award-info":[{"award-number":["HO2402\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jns.2015.06.030","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:18:41Z","timestamp":1434500321000},"page":"129-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease"],"prefix":"10.1016","volume":"356","author":[{"given":"Carmen","family":"Noelker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-0121","authenticated-orcid":false,"given":"Matthias","family":"H\u00f6llerhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Vulinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathrin","family":"Sturn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Roscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne C.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alvarez-Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmann","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.:S29","key":"10.1016\/j.jns.2015.06.030_bb0005","article-title":"Gaucher's disease. Enzyme therapy is not enough","volume":"358","author":"Grabowski","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2015.06.030_bb0010","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jns.2015.06.030_bb0015","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2015.06.030_bb0020","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.06.030_bb0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease","volume":"20","author":"Lesage","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jns.2015.06.030_bb0030","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.06.030_bb0035","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/mds.22538","article-title":"The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism","volume":"24","author":"DePaolo","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2015.06.030_bb0040","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","article-title":"Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers","volume":"78","author":"Anheim","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.06.030_bb0045","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.jns.2015.06.030_bb0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2015.06.030_bb0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jns.2015.06.030_bb0060","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/brain\/awu002","article-title":"Glucocerebrosidase is shaking up the synucleinopathies","volume":"137","author":"Siebert","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.jns.2015.06.030_bb0065","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1038\/emm.2014.128","article-title":"Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation","volume":"47","author":"Bae","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jns.2015.06.030_bb0070","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","article-title":"Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism","volume":"30","author":"Manning-Bog","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jns.2015.06.030_bb0075","doi-asserted-by":"crossref","first-page":"e1005065","DOI":"10.1371\/journal.pgen.1005065","article-title":"Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein","volume":"11","author":"Uemura","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/j.jns.2015.06.030_bb0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/TCRM.S6865","article-title":"Review of miglustat for clinical management in Gaucher disease type 1","volume":"4","author":"Ficicioglu","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jns.2015.06.030_bb0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2015.06.030_bb0090","first-page":"135","article-title":"The parkinsonian toxin MPTP: action and mechanism","volume":"16","author":"Przedborski","year":"2000","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.jns.2015.06.030_bb0095","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1471-4159.2008.05651.x","article-title":"Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid","volume":"107","author":"Alvarez-Fischer","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2015.06.030_bb0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/334345a0","article-title":"Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease","volume":"334","author":"Hirsch","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.jns.2015.06.030_bb0105","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nn.2916","article-title":"Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults","volume":"14","author":"Alvarez-Fischer","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2015.06.030_bb0110","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Franklin KBJaP","year":"1997"},{"key":"10.1016\/j.jns.2015.06.030_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1471-4159.1996.66020733.x","article-title":"Ceramide induces apoptosis in cultured mesencephalic neurons","volume":"66","author":"Brugg","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2015.06.030_bb0120","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1523\/JNEUROSCI.5668-03.2004","article-title":"Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels","volume":"24","author":"Salthun-Lassalle","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2015.06.030_bb0125","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/mol.64.3.578","article-title":"Prevention of dopaminergic neuronal death by cyclic AMP in mixed neuronal\/glial mesencephalic cultures requires the repression of presumptive astrocytes","volume":"64","author":"Mourlevat","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jns.2015.06.030_bb0130","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1471-4159.1990.tb01935.x","article-title":"Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility","volume":"54","author":"Michel","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2015.06.030_bb0135","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.neurobiolaging.2014.01.027","article-title":"Trifluoperazine rescues human dopaminergic cells from wild-type alpha-synuclein-induced toxicity","volume":"35","author":"Hollerhage","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2015.06.030_bb0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-61779-382-0_3","article-title":"High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle","volume":"810","author":"Pesta","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jns.2015.06.030_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neulet.2011.11.035","article-title":"Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease","volume":"507","author":"Noelker","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jns.2015.06.030_bb0150","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jnc.12343","article-title":"Probenecid potentiates MPTP\/MPP+ toxicity by interference with cellular energy metabolism","volume":"127","author":"Alvarez-Fischer","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2015.06.030_bb0155","doi-asserted-by":"crossref","first-page":"e12962","DOI":"10.1371\/journal.pone.0012962","article-title":"Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts","volume":"5","author":"Grunewald","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2015.06.030_bb0160","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1471-4159.1997.69041499.x","article-title":"Rescue of mesencephalic dopamine neurons by anticancer drug cytosine arabinoside","volume":"69","author":"Michel","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2015.06.030_bb0165","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2015.06.030_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","article-title":"Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage","volume":"62","author":"Cleeter","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jns.2015.06.030_bb0175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002808","article-title":"A lysosomal lair for a pathogenic protein pair","volume":"3","author":"Dawson","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2015.06.030_bb0180","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuro.2004.05.002","article-title":"Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration","volume":"25","author":"Drolet","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jns.2015.06.030_bb0185","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0306-4522(03)00036-8","article-title":"Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice","volume":"118","author":"Schluter","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.jns.2015.06.030_bb0190","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.expneurol.2007.10.012","article-title":"Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice","volume":"210","author":"Alvarez-Fischer","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2015.06.030_bb0195","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nbd.2005.08.018","article-title":"Mice lacking alpha-synuclein are resistant to mitochondrial toxins","volume":"21","author":"Klivenyi","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2015.06.030_bb0200","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease\u2014links to Parkinson's disease","volume":"17","author":"Osellame","year":"2013","journal-title":"Cell Metab."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15003718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15003718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T14:54:47Z","timestamp":1537541687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X15003718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":40,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0022510X15003718"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2015.06.030","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2015.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}